

Sylvain Garciaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2433173/publications.pdf>

Version: 2024-02-01

38
papers

467
citations

933447

10
h-index

752698

20
g-index

40
all docs

40
docs citations

40
times ranked

882
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of chemotherapy or chemo-immunotherapy combination after failed anti-CD20 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. American Journal of Hematology, 2018, 93, 1042-1049.	4.1	87
2	Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica, 2014, 99, 527-534.	3.5	73
3	Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematological Oncology, 2014, 32, 187-191.	1.7	42
4	Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. American Journal of Hematology, 2018, 93, 729-735.	4.1	31
5	Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity. Nucleic Acids Research, 2018, 46, 3339-3350.	14.5	26
6	Lenalidomide for the treatment of B-cell lymphoma. Expert Opinion on Investigational Drugs, 2016, 25, 1103-1116.	4.1	20
7	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplantation, 2020, 55, 1076-1084.	2.4	20
8	Patients' Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings. PLoS ONE, 2016, 11, e0154969.	2.5	19
9	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. Cancer Discovery, 2022, 12, 774-791.	9.4	18
10	Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites. Haematologica, 2015, 100, e155-e157.	3.5	17
11	Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers, 2022, 14, 2025.	3.7	17
12	Rituximab (ABVD) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. British Journal of Haematology, 2016, 175, 735-737.	2.5	11
13	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. Clinical Epigenetics, 2019, 11, 141.	4.1	11
14	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. Leukemia and Lymphoma, 2019, 60, 2802-2805.	1.3	10
15	Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers, 2021, 13, 5608.	3.7	10
16	Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. Journal of Cancer, 2014, 5, 248-252.	2.5	9
17	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. Haematologica, 2015, 100, e423-e427.	3.5	7
18	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. Leukemia and Lymphoma, 2014, 55, 1849-1853.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Acute Immune Hematological Complication of Oxaliplatin. A Series of 3 Cases. <i>Tumori</i> , 2014, 100, e17-e19.	1.1	5
20	Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers. <i>Blood</i> , 2017, 130, 652-652.	1.4	5
21	Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/MLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF. <i>PLoS ONE</i> , 2020, 15, e0228878.	2.5	4
22	Lower Relapse and Better PFS Among Chemosensitive Patients Undergoing Allogeneic Transplantation By Haploidentical Compared With HLA-Identical DONOR: Results On A Cohort Of 94 Patients With Hodgkinâ€™S Lymphoma. <i>Blood</i> , 2013, 122, 2144-2144.	1.4	4
23	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. <i>Bone Marrow Transplantation</i> , 2022, 57, 627-632.	2.4	4
24	Primary dedifferentiated liposarcoma of the dura mater: case report. <i>Acta Neurochirurgica</i> , 2012, 154, 1737-1738.	1.7	2
25	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. <i>Oncotarget</i> , 2017, 8, 85110-85119.	1.8	2
26	Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.. <i>Blood</i> , 2020, 136, 14-15.	1.4	2
27	Clinical and biological aspects of aggressive B-cell non-Hodgkin lymphoma in adolescents and young adults. <i>Clinical Oncology in Adolescents and Young Adults</i> , 0, , 115.	0.8	1
28	The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study. <i>Blood</i> , 2016, 128, 1825-1825.	1.4	1
29	IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group. <i>Blood</i> , 2020, 136, 39-40.	1.4	1
30	Prognostic factors and treatment of acute myeloid leukemias in adults (except for APL). <i>Hematologie</i> , 2013, 19, 69-77.	0.0	0
31	B-cell lymphoma. <i>Hematologie</i> , 2015, 21, 16-22.	0.0	0
32	Cellular immunotherapy for hematological malignancies. <i>Hematologie</i> , 2015, 21, 237-246.	0.0	0
33	Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).. <i>Blood</i> , 2012, 120, 3096-3096.	1.4	0
34	Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd. <i>Blood</i> , 2013, 122, 3221-3221.	1.4	0
35	Haploidentical stem cell transplantation (Haplo-HSCT) with nonmyeloablative conditioning regimen (NMAC) and postinfusion cyclophosphamide in advanced non-Hodgkin lymphoma (NHL) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7039-7039.	1.6	0
36	Allogeneic hematopoietic stem cell transplantation in a cohort of 314 advanced lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8568-8568.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma. Blood, 2014, 124, 3863-3863.	1.4	0
38	Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia. Blood, 2020, 136, 23-23.	1.4	0